QNCX - NASDAQ
Quince Therapeutics, Inc.
$1.36
+0.0000%Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotQuince Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Quince Therapeutics, Inc. Cash Flow Statement
QNCX • NASDAQ
| Quince Therapeutics, Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-56.8M | -31.4M | -51.7M | -89.9M | -76.8M | -37M | -12.5M | -12.2M | |
186K | 322K | 204K | 344K | 332K | 188K | 51K | 45K | |
0.0 | -248K | -284K | 878K | 635K | -812K | -145K | 222K | |
4.7M | 5.2M | 16.6M | 29.9M | 14.5M | 2.1M | 155K | 38K | |
20.5M | 5.8M | 913K | 199K | 367K | 367K | 1.1M | 1.6M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1K) | (1K) | |
-484K | 2M | -9.8M | -4.3M | 10.2M | 1.9M | -390K | 460K | |
-31.9M | -18.3M | -44M | -62.9M | -50.8M | -33.3M | -11.7M | -9.8M | |
INVESTING ACTIVITIES | ||||||||
-257K | -160K | -133K | -180K | -52K | -55K | -212K | -77K | |
(0.0) | -2.1M | (10.6M) | -59M | (52.4M) | -812K | (0.0) | (0.0) | |
-89.6M | -113.8M | -75M | -38.8M | -187.1M | -135.4M | -55.2M | (0.0) | |
109.4M | 111.2M | 82.5M | 97.9M | 134.8M | 117.7M | 8.7M | 0.0 | |
2.3M | -910K | 70K | 59M | -52.4M | 812K | -46.5M | 0.0 | |
(21.9M) | -5.8M | (18M) | (59M) | -52.4M | -17.7M | -46.8M | -77K | |
FINANCING ACTIVITIES | ||||||||
225K | 149K | 608K | 6.8M | 117.6M | 77.8M | 0.0 | 0.0 | |
0.0 | -6K | -49K | 0.0 | -34K | -559K | 250K | 7.8M | |
-5M | 0.0 | 148K | 0.0 | 1.3M | 98K | -10K | 0.0 | |
-4.8M | 143K | 707K | 6.8M | 118.9M | 77.4M | 75.9M | 7.8M | |
CASH FLOW SUMMARY | ||||||||
231K | 80K | 184K | 55K | 0.0 | 0.0 | 0.0 | 0.0 | |
-14.5M | -23.8M | -25.1M | 2.9M | 15.6M | 26.3M | 17.5M | -2.2M | |
20.8M | 44.6M | 69.7M | 66.8M | 51.2M | 24.9M | 7.4M | 9.5M | |
6.2M | 20.8M | 44.6M | 69.7M | 66.8M | 51.2M | 24.9M | 7.4M | |
-32.2M | -18.5M | -44.2M | -63.1M | -50.9M | -33.3M | -11.9M | -9.9M |
SEC Filings
QNCX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | January 29, 2026 | January 29, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 17, 2025 | October 17, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 26, 2025 | September 25, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 11, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 11, 2025 | August 11, 2025 | 2025 | |
S-3 S-3 N/A | July 25, 2025 | July 25, 2025 | ||
8-K 8-K 2025 N/A | July 16, 2025 | July 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 13, 2025 | June 12, 2025 | 2025 |
Related Guides
Continue your QNCX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.